FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891763961> ?p ?o ?g. }

• W2891763961 endingPage "3548" @default.
• W2891763961 startingPage "3548" @default.
• W2891763961 abstract "3548 Background: MMR or MSI testing is recommended for mCRC pts and is often done locally by IHC or PCR testing, respectively (NCCN V1.2017) Nivo, a fully human anti-PD-1 mAb, demonstrated durable responses and a 12-mo OS rate of 73.8% in pts with mCRC locally assessed for dMMR/MSI-H status in the CheckMate 142 study (NCT02060188; Overman M, et al. 2017). Here we describe the results of local and central testing with respect to MMR/MSI status and clinical outcomes in the CheckMate 142 study. Methods: MMR/MSI status was assessed locally on archival tumor using IHC/PCR at screening and confirmed centrally by PCR (modified Bethesda panel) testing of tumor biopsy at enrollment. dMMR was defined by IHC as a loss of expression in ≥1 mismatch repair proteins. Stable microsatellite (MSS), low MSI (MSI-L), and high MSI (MSI-H), were defined as instability in 0, 1, or ≥2 markers, respectively. Pts with dMMR/MSI-H mCRC who progressed on or were intolerant of ≥1 prior line of therapy received nivo 3 mg/kg Q2W. Results: 74 pts were dMMR/MSI-H by local testing. Of these pts, 53 (72%) were centrally confirmed as MSI-H, 7 pts had insufficient tissue sample for PCR testing, and 14 pts had a central test that did not match local test results. Of the 14 pts, 3 pts with a clinical history of LS were identified locally as dMMR but centrally as MSS (Table). INV-reported ORR was 31.1% in 74 pts locally determined as dMMR/MSI-H, 35.8% in 53 pts locally and centrally confirmed as MSI-H, and 21.4% in 14 pts not centrally confirmed as MSI-H. Conclusions: The similar clinical activity between pts locally confirmed as MSI-H and pts who were centrally confirmed as MSI-H suggest local testing is appropriate for identifying the dMMR/MSI-H pts who may benefit from nivo monotherapy. Clinical trial information: NCT02060188. [Table: see text]" @default.
• W2891763961 created "2018-09-27" @default.
• W2891763961 creator A5003827387 @default.
• W2891763961 creator A5006249276 @default.
• W2891763961 creator A5009193095 @default.
• W2891763961 creator A5013977667 @default.
• W2891763961 creator A5017619486 @default.
• W2891763961 creator A5034704814 @default.
• W2891763961 creator A5034884991 @default.
• W2891763961 creator A5043091366 @default.
• W2891763961 creator A5045441776 @default.
• W2891763961 creator A5051613962 @default.
• W2891763961 creator A5060058983 @default.
• W2891763961 creator A5061348179 @default.
• W2891763961 creator A5069877747 @default.
• W2891763961 creator A5074731037 @default.
• W2891763961 creator A5078038970 @default.
• W2891763961 creator A5079480540 @default.
• W2891763961 creator A5081403428 @default.
• W2891763961 creator A5082449165 @default.
• W2891763961 creator A5088841234 @default.
• W2891763961 creator A5090464803 @default.
• W2891763961 date "2017-05-20" @default.
• W2891763961 modified "2023-10-17" @default.
• W2891763961 title "Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study." @default.
• W2891763961 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.3548" @default.
• W2891763961 hasPublicationYear "2017" @default.
• W2891763961 type Work @default.
• W2891763961 sameAs 2891763961 @default.
• W2891763961 citedByCount "5" @default.
• W2891763961 countsByYear W28917639612020 @default.
• W2891763961 countsByYear W28917639612021 @default.
• W2891763961 countsByYear W28917639612022 @default.
• W2891763961 countsByYear W28917639612023 @default.
• W2891763961 crossrefType "journal-article" @default.
• W2891763961 hasAuthorship W2891763961A5003827387 @default.
• W2891763961 hasAuthorship W2891763961A5006249276 @default.
• W2891763961 hasAuthorship W2891763961A5009193095 @default.
• W2891763961 hasAuthorship W2891763961A5013977667 @default.
• W2891763961 hasAuthorship W2891763961A5017619486 @default.
• W2891763961 hasAuthorship W2891763961A5034704814 @default.
• W2891763961 hasAuthorship W2891763961A5034884991 @default.
• W2891763961 hasAuthorship W2891763961A5043091366 @default.
• W2891763961 hasAuthorship W2891763961A5045441776 @default.
• W2891763961 hasAuthorship W2891763961A5051613962 @default.
• W2891763961 hasAuthorship W2891763961A5060058983 @default.
• W2891763961 hasAuthorship W2891763961A5061348179 @default.
• W2891763961 hasAuthorship W2891763961A5069877747 @default.
• W2891763961 hasAuthorship W2891763961A5074731037 @default.
• W2891763961 hasAuthorship W2891763961A5078038970 @default.
• W2891763961 hasAuthorship W2891763961A5079480540 @default.
• W2891763961 hasAuthorship W2891763961A5081403428 @default.
• W2891763961 hasAuthorship W2891763961A5082449165 @default.
• W2891763961 hasAuthorship W2891763961A5088841234 @default.
• W2891763961 hasAuthorship W2891763961A5090464803 @default.
• W2891763961 hasConcept C104317684 @default.
• W2891763961 hasConcept C121608353 @default.
• W2891763961 hasConcept C126322002 @default.
• W2891763961 hasConcept C143998085 @default.
• W2891763961 hasConcept C160798450 @default.
• W2891763961 hasConcept C180754005 @default.
• W2891763961 hasConcept C2777701055 @default.
• W2891763961 hasConcept C2779767149 @default.
• W2891763961 hasConcept C2780030458 @default.
• W2891763961 hasConcept C526805850 @default.
• W2891763961 hasConcept C55493867 @default.
• W2891763961 hasConcept C60748783 @default.
• W2891763961 hasConcept C61320498 @default.
• W2891763961 hasConcept C71924100 @default.
• W2891763961 hasConcept C86803240 @default.
• W2891763961 hasConceptScore W2891763961C104317684 @default.
• W2891763961 hasConceptScore W2891763961C121608353 @default.
• W2891763961 hasConceptScore W2891763961C126322002 @default.
• W2891763961 hasConceptScore W2891763961C143998085 @default.
• W2891763961 hasConceptScore W2891763961C160798450 @default.
• W2891763961 hasConceptScore W2891763961C180754005 @default.
• W2891763961 hasConceptScore W2891763961C2777701055 @default.
• W2891763961 hasConceptScore W2891763961C2779767149 @default.
• W2891763961 hasConceptScore W2891763961C2780030458 @default.
• W2891763961 hasConceptScore W2891763961C526805850 @default.
• W2891763961 hasConceptScore W2891763961C55493867 @default.
• W2891763961 hasConceptScore W2891763961C60748783 @default.
• W2891763961 hasConceptScore W2891763961C61320498 @default.
• W2891763961 hasConceptScore W2891763961C71924100 @default.
• W2891763961 hasConceptScore W2891763961C86803240 @default.
• W2891763961 hasIssue "15_suppl" @default.
• W2891763961 hasLocation W28917639611 @default.
• W2891763961 hasOpenAccess W2891763961 @default.
• W2891763961 hasPrimaryLocation W28917639611 @default.
• W2891763961 hasRelatedWork W2603025908 @default.
• W2891763961 hasRelatedWork W2891763961 @default.
• W2891763961 hasRelatedWork W2911032670 @default.
• W2891763961 hasRelatedWork W3111191926 @default.
• W2891763961 hasRelatedWork W3118206804 @default.
• W2891763961 hasRelatedWork W3206999910 @default.
• W2891763961 hasRelatedWork W3210186410 @default.
• W2891763961 hasRelatedWork W4214771124 @default.
• W2891763961 hasRelatedWork W4235974995 @default.

• next